Population Pharmacokinetics (poppk) and Exposure-Response (ER) Analyses to Confirm the Global Alectinib (ALC) 600mg BID Dose in the Chinese Treatment-Naïve Population.

Joy Hsu,Felix Jaminion,Alice Shaw,Caicun Zhou,Tony Mok,Tomohide Tamura,Tomohiro Tanaka,Emmanuel Mitry,Elena Guerini,Eveline Nuesch,Bogdana Balas,Ali Hassan Zeaiter,Peter N. Morcos,Nicolas Frey

DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.e21133

IF: 45.3

2018-01-01

Journal of Clinical Oncology

Abstract:e21133 Background: Phase III studies conducted in Japanese (J-ALEX; JapicCTI-132316) and global (ALEX; NCT02075840) patients with treatment-naïve ALK+ NSCLC demonstrated superiority of ALC 300 and 600mg BID, respectively, versus crizotinib 250mg BID. PopPK and ER analyses established the appropriateness of ALC 600mg BID dose in the global population to achieve exposures above an optimal exposure threshold (Hsu et al. ASCPT 2018; abstract 824). Analyses were updated with emerging PK data from the ongoing phase III study ALESIA (NCT02838420) in Chinese treatment-naïve ALK+ NSCLC patients. Methods: A previously developed PopPK model (Hsu et al, ASCO 2016; abstract e20598) was applied to the collected PK data from ALESIA (n = 95). Using methods previously described, the model was then used to conduct PK simulations in Chinese patients for ALC 300mg and 600mg BID doses to determine the proportion of patients falling above and below the previously identified optimal PK exposure for PFS from Cox proportional hazards analysis. Results: The PopPK models adequately describe the PK of ALC in Chinese treatment-naïve ALK+ NSCLC patients. Body weight remained the only significant covariate for ALC PK with lower exposure at increasing body weight. No effect of race or ethnicity were confirmed in popPK analyses. PK simulations indicate 51% and 4% of alectinib treated Chinese patients would fall below the identified optimal exposure threshold for 300 and 600mg BID, respectively. ALC 600mg BID maximizes the expected PFS benefit while lower ALC doses could result in reduced efficacy. No significant exposure-safety relationships were seen from previous ALC PopPK and ER analyses. Conclusions: The Global ALC 600mg BID is the recommended dose in the Chinese ALK TKI treatment-naive population. Clinical trial information: JapicCTI-132316; NCT02075840.